Oppenheimer Asset Management Inc. Buys 2,227 Shares of IDEAYA Biosciences, Inc. $IDYA

Oppenheimer Asset Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 19.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,787 shares of the company’s stock after acquiring an additional 2,227 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IDEAYA Biosciences were worth $290,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. State of New Jersey Common Pension Fund D raised its stake in shares of IDEAYA Biosciences by 11.1% in the second quarter. State of New Jersey Common Pension Fund D now owns 100,827 shares of the company’s stock valued at $2,119,000 after acquiring an additional 10,047 shares during the last quarter. CWM LLC raised its stake in shares of IDEAYA Biosciences by 33.0% in the second quarter. CWM LLC now owns 3,153 shares of the company’s stock valued at $66,000 after acquiring an additional 782 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in shares of IDEAYA Biosciences in the second quarter valued at approximately $216,000. KLP Kapitalforvaltning AS grew its holdings in shares of IDEAYA Biosciences by 16.1% during the second quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the company’s stock worth $364,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Platinum Investment Management Ltd. grew its holdings in shares of IDEAYA Biosciences by 9.3% during the second quarter. Platinum Investment Management Ltd. now owns 166,917 shares of the company’s stock worth $3,509,000 after purchasing an additional 14,204 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Up 0.8%

IDEAYA Biosciences stock opened at $31.86 on Monday. The business’s 50-day simple moving average is $26.96 and its 200 day simple moving average is $23.35. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of -8.41 and a beta of 0.14. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $33.64.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same period in the previous year, the company earned ($0.68) earnings per share. The business’s revenue for the quarter was up NaN% on a year-over-year basis. As a group, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on IDYA shares. Stephens restated an “overweight” rating and set a $45.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. The Goldman Sachs Group increased their target price on IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Guggenheim started coverage on IDEAYA Biosciences in a report on Thursday, September 18th. They set a “buy” rating and a $50.00 target price on the stock. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, TD Cowen started coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a “buy” rating on the stock. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.13.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.